Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics IncfiledCriticalAmicus Therapeutics Inc
Publication of AR122298A1publicationCriticalpatent/AR122298A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Se proporcionan métodos para tratar un paciente diagnosticado con la enfermedad de Fabry y métodos para mejorar la a-galactosidasa A en un paciente diagnosticado o con sospecha de padecer la enfermedad de Fabry. Algunos métodos comprenden administrar a un paciente una dosis terapéuticamente eficaz de una chaperona farmacológica para a-galactosidasa A, donde el paciente tiene una mutación en la secuencia de ácido nucleico que codifica la a-galactosidasa A. También se describen usos de chaperonas farmacológicas para el tratamiento de la enfermedad de Fabry y composiciones para su uso en el tratamiento de la enfermedad de Fabry.Methods of treating a patient diagnosed with Fabry disease and methods of improving α-galactosidase A in a patient diagnosed with or suspected of having Fabry disease are provided. Some methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for α-galactosidase A, where the patient has a mutation in the nucleic acid sequence encoding α-galactosidase A. Uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.
ARP200102261A2019-08-072020-08-07
METHODS TO TREAT FABRY DISEASE IN PATIENTS WHO HAVE A MUTATION IN THE GLA GENE
AR122298A1
(en)
USE OF LAQUINIMOD FOR THE TREATMENT OF PATIENTS WITH CROHN'S DISEASE IN THOSE WHO FAILS AN ANTI-FACTOR THUMOR NECROSIS THERAPY a (ANTI-TNFa) FIRST LINE
Method for administering tasimelteon to a human patient that includes oral administration of an effective dose under fasting conditions to treat a circadian rhythm disorder or a sleep disorder, such as sleep-wake disorder other than 24 hours non-24 method for shorten the tmax of tasimelteon in a human patient who is being treated with tasimelteon.